Current rheumatology reviews最新文献

{"title":"Antidrug Antibodies and Serum Etanercept Levels in Rheumatoid Arthritis: A Narrative Review.","authors":"Anfal A Abdulla, Ali A Younis, Mohammed I Aladul","doi":"10.2174/0115733971461589260523231223","DOIUrl":"https://doi.org/10.2174/0115733971461589260523231223","url":null,"abstract":"<p><strong>Introduction/objective: </strong>Etanercept is a tumor necrosis factor inhibitor used widely for rheumatoid arthritis. Because patients respond differently, clinicians have increasingly explored whether measuring drug levels and antidrug antibodies could help guide treatment. This review brings together what is currently known about etanercept immunogenicity, serum concentrations, and the role of therapeutic drug monitoring, with a particular focus on practice in resource-limited settings such as Iraq.</p><p><strong>Methods: </strong>Major databases were searched (January 2010-June 2025) for clinical trials, observational studies, and systematic reviews of adults with rheumatoid arthritis receiving originator or biosimilar etanercept that reported antidrug antibodies, serum levels, or outcomes related to monitoring.</p><p><strong>Results: </strong>Across randomized and real-world studies, etanercept generally showed low immunogenicity, with reported antidrug antibodies mostly below 15% and neutralizing antibodies rarely detected. Serum levels varied considerably between patients, and no robust therapeutic range could be defined. In most studies, etanercept concentrations did not consistently predict clinical response, and originator and biosimilar products appeared similar in terms of effectiveness and safety.</p><p><strong>Discussion: </strong>Overall, these findings suggest that immunogenicity is not a major reason for etanercept treatment failure and that routine therapeutic drug monitoring is unlikely to help most patients. However, the evidence is heterogeneous, and real-world data from low- and middleincome countries, including Iraq, are still limited.</p><p><strong>Conclusion: </strong>Current evidence supports etanercept and its biosimilars as low-immunogenic options for rheumatoid arthritis, where routine monitoring is usually unnecessary. A more practical strategy may be to reserve targeted testing for selected non-responders while strengthening pharmacovigilance and local real-world research.</p>","PeriodicalId":11188,"journal":{"name":"Current rheumatology reviews","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148204523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal Associations Between Nine Autoimmune Diseases and Idiopathic Thrombocytopenic Purpura: A Mendelian Randomization Study.","authors":"Xin Yang, Kaige Gao, Suyin Yang, Zhenyu Wang, Min Tang, Xun Gong","doi":"10.2174/0115733971469346260523230227","DOIUrl":"https://doi.org/10.2174/0115733971469346260523230227","url":null,"abstract":"<p><strong>Introduction: </strong>Clinical evidence suggests the presence of comorbidity between Autoimmune diseases (ADs) and secondary Idiopathic thrombocytopenic purpura (ITP), whereas the underlying causal relationship remains to be established. This study employed Mendelian Randomization (MR) analysis to investigate potential causal relationships between multiple common ADs and the risk of ITP.</p><p><strong>Methods: </strong>Using criteria of P<5×10-8 , P<5×10-6 , and F-statistic>10, and excluding single nucleotide polymorphisms (SNPs) with confounding, palindromic sequences, and linkage disequilibrium as instrumental variables (IVs). The primary analysis was conducted using the inverse-variance weighted (IVW) method, supplemented by MR-Egger regression, weighted median estimator (WME), simple mode, and weighted mode approaches to assess robustness. Multiple sensitivity analyses were conducted to assess the robustness of the findings.</p><p><strong>Results: </strong>SNPs significantly associated with each autoimmune disease were identified as IVs, including 6 SNPs for systemic lupus erythematosus (SLE), 5 for rheumatoid arthritis (RA), 6 for ankylosing spondylitis (AS), 5 for Sjögren's syndrome (SS), 7 for polymyositis (PM), 13 for primary sclerosing cholangitis (PSC), 4 for primary biliary cirrhosis (PBC), 16 for psoriatic arthritis (PsA), and 25 for adult-onset Still's disease (AOSD). IVW analysis indicated no genetic association between SLE, RA, AS, PBC, PsA, or AOSD and ITP. Significant associations were observed for PM (OR=0.807, 95% CI=0.742-0.876, P=3.93×10⁻⁷), PSC (OR=0.831, 95% CI=0.742-0.933, P=0.002), and SS (OR=1.589, 95% CI=1.375-1.835, P=3.05×10⁻¹⁰). WME analysis yielded consistent results for PM, PSC, and SS. Most sensitivity analyses supported the robustness of these findings.</p><p><strong>Discussion: </strong>This study preliminarily explored the genetic relationship between ADs and ITP, but it is subject to several limitations, such as the limited number of IVs. Larger-scale genome-wide association study (GWAS) datasets will be needed for further validation.</p><p><strong>Conclusions: </strong>MR analysis suggested that there might be no significant causal associations between SLE, RA, AS, PBC, PsA, or AOSD and ITP, whereas PM, PSC, and SS might potentially show causal associations with ITP.</p>","PeriodicalId":11188,"journal":{"name":"Current rheumatology reviews","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148204530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interrelationship Between Depression and Disease Activity in Rheumatoid Arthritis: A Systematic Review and Meta-analysis Using HADS, PHQ-9, BDI, CES-D, SDS, and DAS28 Tools.","authors":"Khushi Lamba, Unnati Jain, Shushank Mahajan, Samrat Chauhan, Sanjana Mehta, Sanchit Dhankhar","doi":"10.2174/0115733971461795260517100253","DOIUrl":"https://doi.org/10.2174/0115733971461795260517100253","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and progressive destruction of cartilage and bones. In the world, RA affects 0.2-1.2% of the population, and the highest percentage of those affected is women. Depression has been identified as a comorbid condition of RA. This condition tends to increase pain as well as the intensity of RA. The objective of this study is to systematically analyse the prevalence rates, risk factors, and effects of depression among RA patients and establish the knowledge gaps that should inform improved comprehensive management.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This systematic review adhered to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) protocol. Electronic databases PubMed, Google Scholar, and Scopus database from 2015 to 2025. Cross-sectional studies involving adults aged 18 years and above diagnosed with rheumatoid arthritis (RA) and assessed using validated measures of depression. Data analysis of the results was performed using SPSS version 26.0. A forest plot was generated through meta-analysis to calculate the pooled prevalence within the study population. Heterogeneity among studies was examined using the I2 statistic and the Cochran's Q test. The protocol for this systematic review and meta-analysis was registered with PROSPERO (International Prospective Register of Systematic Reviews) with registration no. CRD420261287407.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Out of 9,950 initially identified records, only 19 studies were included. The pooled prevalence of depression was high and varied depending on the diagnostic instrument used and the age group considered. The highest prevalence was observed among the subjects aged 50-60 years. Higher detection rates were reported with the Hospital Anxiety and Depression Scale (HADS) and the Patient Health Questionnaire -9 (PHQ-9). Depression was found to be associated with greater disease activity, fatigue, pain, lower quality of life, and treatment non-adherence.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Discussion: &lt;/strong&gt;This meta-analysis highlights that depression is a highly prevalent comorbid condition among RA patients, with a pooled prevalence of 39.31%. Substantial heterogeneity across studies (I2 = 96.9%) suggests that variation exists in diagnostic tools, population characteristics, and regional contexts. Higher prevalence rates were observed in Middle Eastern and South Asian populations; this might be influenced by socioeconomic factors, healthcare accessibility, and cultural stigma in mental health reporting.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Depression has been found to have a high prevalence among RA patients across diverse populations. The interpretation is limited by the inclusion of cross-sectional studies and high heterogeneity. The findings support the routine depression screening and management in RA patients. Future research should investigate the development of RA in d","PeriodicalId":11188,"journal":{"name":"Current rheumatology reviews","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148204542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary Factor X Deficiency Associated with Sjögren's Syndrome: A Rare Case Report.","authors":"Dilek Keskin, Ozlem Candan","doi":"10.2174/0115733971468472260515063132","DOIUrl":"https://doi.org/10.2174/0115733971468472260515063132","url":null,"abstract":"<p><strong>Background: </strong>Acquired factor X deficiency (AFXD) is considered a rare but clinically significant cause of coagulation disorders, predominantly associated with systemic AL amyloidosis. Autoimmune-mediated AFXD is very rare, and a clear, well-documented association with Sjögren's syndrome has not yet been reported.</p><p><strong>Case presentation: </strong>A 60-year-old woman with hypertension presented with chest pain. Despite normal liver function and absence of monoclonal gammopathy, she was found to have significantly prolonged PT/INR and severe factor X deficiency (3%). During follow-up, she developed symptoms of dry eyes, and autoimmune serology was positive for ANA, anti-SSA, and anti-SSB, meeting the 2016 ACR/EULAR criteria for Sjögren's syndrome. After ruling out alternative causes, she was diagnosed with autoimmune-mediated AFXD. Despite the severe deficiency, she did not present with any significant bleeding symptoms. Prednisone treatment (1 mg/kg/day) led to partial biochemical improvement.</p><p><strong>Conclusion: </strong>This report describes the first known association between Sjögren's syndrome and AFXD. Furthermore, the case highlights the importance of considering autoimmune etiologies in cases of unexplained coagulopathy and demonstrates the disconnect between laboratory abnormalities and bleeding phenotypes.</p>","PeriodicalId":11188,"journal":{"name":"Current rheumatology reviews","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148143015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decoding Rheumatoid Arthritis Comorbidities: Molecular Mechanisms and Computational Advances.","authors":"Min Tang, Yinglu Guo, Peng Lü, Bin Wang, Xun Gong","doi":"10.2174/0115733971435940260424115013","DOIUrl":"https://doi.org/10.2174/0115733971435940260424115013","url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent systemic inflammation that extends far beyond the joints, giving rise to a wide range of comorbidities, including metabolic disorders, neurodegenerative conditions, osteoporosis, and various malignancies. These complications not only accelerate disease progression but also profoundly impair patient quality of life and overall survival. Understanding the molecular mechanisms that connect RA with its comorbidities is therefore essential for advancing risk prediction, enabling early diagnosis, and developing personalized therapeutic strategies. Traditional observational studies have provided valuable epidemiological evidence, yet they are frequently hampered by confounding variables and reverse causation. In recent years, rapid progress in computational methodologies has transformed RA research, offering more precise and unbiased approaches to dissect disease mechanisms. Large-scale retrospective analyses strengthen statistical associations, whereas bioinformatics pipelines and machine learning algorithms contribute to biomarker discovery, disease classification, and risk stratification. Mendelian Randomization has emerged as a powerful genetic tool for identifying causal relationships between RA and its comorbidities by employing genetic variants as instrumental variables. Furthermore, the integration of multi-omics layers-including genomics, transcriptomics, proteomics, and epigenomics-has greatly expanded insights into shared pathogenic pathways and unveiled promising therapeutic targets. Artificial intelligence-driven predictive models further enhance disease risk estimation and enable patient stratification based on molecular signatures, paving the way toward precision medicine in RA management. Collectively, this review highlights recent computational advances, underscoring their role in refining predictive models, elucidating mechanistic links between RA and comorbidities, and guiding the development of targeted therapeutic interventions to improve long-term patient outcomes.</p>","PeriodicalId":11188,"journal":{"name":"Current rheumatology reviews","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147981007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematological Side Effects of Methotrexate in Rheumatoid Arthritis: A Systematic Review.","authors":"Zaidagul Kystaubayeva, Meruyert Zhakupbekova, Ainur Mukhamedjanova, Riza Nurpeissova","doi":"10.2174/0115733971454973260424092936","DOIUrl":"https://doi.org/10.2174/0115733971454973260424092936","url":null,"abstract":"<p><strong>Introduction: </strong>Methotrexate (MTX) is a cornerstone therapy for rheumatoid arthritis (RA), yet its hematological toxicity remains a significant clinical concern. This systematic review synthesizes evidence on MTX-induced hematological side effects to inform safer management.</p><p><strong>Methods: </strong>A comprehensive search of Medline/PubMed (1991 to 2024), SCOPUS (1995 to 2024), and the Cochrane Library identified 108 studies reporting hematological adverse events associated with MTX in RA patients. Search terms included \"RA,\" \"MTX,\" and \"hematologic side effects\". Exclusion criteria included the use of biologics or other DMARDs, other rheumatic diseases, and studies focusing on non-hematological side effects.</p><p><strong>Results: </strong>Hematological disorders represent the second most prevalent adverse outcome following gastroenterological disorders. The side effects often include complications such as leukopenia, thrombocytopenia, megaloblastic anemia, and pancytopenia. Risk factors were consistently identified across studies and include renal failure, advanced age, hypoalbuminemia, folate deficiency, dosing errors, and concomitant use of medications. Pancytopenia emerges as a potentially fatal complication, requiring careful monitoring and timely intervention with folinic acid (leucovorin).</p><p><strong>Discussion: </strong>Low-dose MTX, though effective for RA, can lead to significant hematologic side effects such as anemia, leukopenia, thrombocytopenia, and pancytopenia, with reported incidence rates of 2.4-5.6%, exceeding earlier estimates. Dosage errors by patients or healthcare providers demonstrate the potential for fatal outcomes. Risk factors include renal impairment, hypoalbuminemia, infections, advanced age, and inadequate folic acid supplementation. Side effects typically resolve after discontinuation, and MTX can be safely resumed under appropriate monitoring and dose adjustment protocols.</p><p><strong>Conclusion: </strong>Our study summarizes evidence indicating that hematological disorders are commonly reported adverse events following gastroenterological disorders. Pancytopenia represents a potentially fatal complication requiring careful monitoring and timely intervention. This work provides an integrative clinical synthesis of evidence across diverse study designs to inform risk stratification and clinical management.</p>","PeriodicalId":11188,"journal":{"name":"Current rheumatology reviews","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147981049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Otitis Media in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Case Series and Review.","authors":"Alexander S Fedorov, Ruslan M Tursunov, Yulia Y Grabovetskaya, Sergej N Litvinenko, Olga L Kolesnikova, Larisa V Denisova, Lyudmila A Rudyuk, Mikhail M Kostik","doi":"10.2174/0115733971445141260428050607","DOIUrl":"https://doi.org/10.2174/0115733971445141260428050607","url":null,"abstract":"<p><strong>Background: </strong>Otitis media associated with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis represents an underrecognized manifestation of systemic vasculitic diseases, including eosinophilic granulomatosis with polyangiitis (EGPA) and granulomatosis with polyangiitis (GPA). Eosinophilic otitis media shares several clinical and immunological features with localized forms of EGPA, which complicates differential diagnosis. This study presents two cases that illustrate diagnostic and therapeutic challenges and highlight the clinical overlap and heterogeneity of these conditions.</p><p><strong>Case presentation: </strong>A 30-year-old woman with severe asthma, nasal polyposis, and ANCAnegative eosinophilic otitis media reported ear fullness, hearing loss, and otorrhea. She met the diagnostic criteria for EGPA, with peripheral eosinophilia and pulmonary infiltrates. These findings may have been related to dupilumab therapy. Treatment with systemic glucocorticoids and benralizumab led to clinical stabilization. However, symptoms of otitis media with a predominant neutrophilic inflammatory pattern recurred during glucocorticoid tapering. A 65-yearold woman with ANCA-positive GPA presented with systemic manifestations, including weight loss, episcleritis, and pulmonary and renal involvement, as well as otitis media. She achieved clinical improvement following treatment with rituximab and glucocorticoids.</p><p><strong>Conclusion: </strong>Eosinophilic otitis media may represent a local manifestation of eosinophilic granulomatosis with polyangiitis, in which overlapping type 1 and type 2 inflammatory processes complicate classification. The limited number of observations currently precludes definitive conclusions, underscoring the need for further research. In contrast, granulomatosis with polyangiitis is marked by severe systemic involvement. Myeloperoxidase-DNA complexes in middle ear effusion show promise as biomarkers, pending further study. To advance understanding, multicenter studies are essential to refine nosological classification and optimize therapeutic strategies for eosinophilic middle ear disease.</p>","PeriodicalId":11188,"journal":{"name":"Current rheumatology reviews","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147940466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the Relationship between Work-Related Musculoskeletal Disorders and the Quality of Life of Agricultural Workers.","authors":"Reza Faryabi, Shima Groohi-Sardou, Rasoul Raesi, Kiavash Hushmandi, Salman Daneshi, Habibe Vaziri Nasab, Fatemeh Bagher Barahouei, Esmaeil Barkhori Mehni","doi":"10.2174/0115733971355486250528163102","DOIUrl":"10.2174/0115733971355486250528163102","url":null,"abstract":"<p><strong>Background: </strong>Repetitive and heavy physical activities by agricultural workers can lead to the prevalence of musculoskeletal disorders and affect the quality of life of these individuals.</p><p><strong>Materials and methods: </strong>This cross-sectional study was conducted using cluster and convenience sampling on 259 agricultural workers employed in greenhouses in the City of Jiroft in southeastern Iran in the year 2024. Data were collected using the standardized Nordic Musculoskeletal Questionnaire and quality of life questionnaire, and analyzed using descriptive and inferential statistics such as mean, standard deviation, range, frequency, and percentage frequency. Independent t-test and regression were employed in SPSS-16 software at a significance level of 0.05 (p ≤ 0.05).</p><p><strong>Results: </strong>Among the 259 people studied, 120 (46.3%) had a low level and 139 (53.7%) had an average level of quality of life. The level of quality of life has a significant relationship with musculoskeletal disorders, occupation, and underlying disease. Based on this, people who do not have musculoskeletal problems have 2.84 times the chance of having a better quality of life than people who have these problems (95% CI 1.64, 4.94, p < 0.001). Additionally, greenhouse workers have a higher quality of life 2.21 times more than horticulture workers (95% CI 1.41, 4.15, p = 0.001). Furthermore, people without underlying disease have a higher quality of life 2.35 times than those with disease (95% CI 1.26, 4.39, p = 0.007).</p><p><strong>Conclusion: </strong>The quality of life of agricultural workers is low and moderate, and the prevalence of musculoskeletal disorders in workers has decreased the quality of life.</p>","PeriodicalId":11188,"journal":{"name":"Current rheumatology reviews","volume":" ","pages":"74-83"},"PeriodicalIF":1.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discoid Lupus Flare with Chondritis Triggered by Eaton Fire Case Report.","authors":"Sofia Audrey B Gonzales, Kiana Mortezaei, Daniel G Arkfeld","doi":"10.2174/0115733971396962250721111020","DOIUrl":"10.2174/0115733971396962250721111020","url":null,"abstract":"<p><strong>Introduction: </strong>Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disorder with flare-ups often triggered by environmental stressors. While stress is a known trigger for lupus exacerbations, the relationship between environmental stressors, lupus flares, and discoid lupus erythematosus remains underexplored. This case report examines a patient whose symptoms worsened after exposure to the Eaton fire.</p><p><strong>Case presentation: </strong>A 57-year-old female with lupus reported a flare following the Eaton fire, which severely damaged her parents' home. Symptoms began 12 hours after the fire. Examination revealed erythema and deformity in both ears, consistent with chondritis. After starting a prednisone taper, her condition improved within two weeks.</p><p><strong>Conclusion: </strong>Environmental stressors, like natural disasters, can trigger lupus flare-ups and conditions, such as discoid lupus erythematosus (DLE). Stress-induced immune dysregulation exacerbates autoimmune responses, making it challenging to differentiate discoid lupus from other lupus manifestations. This case highlights the need for recognizing environmental triggers in lupus management and further research into the role of stress in lupus flare-ups.</p>","PeriodicalId":11188,"journal":{"name":"Current rheumatology reviews","volume":" ","pages":"1-4"},"PeriodicalIF":1.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psoriatic Arthritis Publications in 2013-2023: A Bibliometric Analysis Based on Web of Science.","authors":"Huidong Chen, Guangliang Wei, Xintong Xie, Chunyan Huang, Xiru Ling, Jie Chen","doi":"10.2174/0115733971370078251029075851","DOIUrl":"10.2174/0115733971370078251029075851","url":null,"abstract":"<p><strong>Introduction: </strong>The study aimed to estimate the quantity and quality of literature related to Psoriatic Arthritis (PSA) between 2013 and 2023 and to provide researchers with an overall understanding of the study and guidance for future research.</p><p><strong>Methods: </strong>Using the search term \"psoriatic arthritis\" on the Web of Science to generate the publication list, we retained original articles and reviews for analysis. The number of articles, active countries, journals, and citation data were identified, and visual maps of collaborative networks were created.</p><p><strong>Results: </strong>There is a statistically significant upward trend (P<0.05) in the number of articles published between 2013 and 2023. The USA, Italy, England, Spain, and Canada were the five countries with the highest output. Ranked by the number of PSA articles published in journals, the top five are: Journal of Rheumatology, Clinical Rheumatology, Rheumatology, Annals of the Rheumatic Diseases, and Clinical and Experimental Rheumatology. Rheumatoid arthritis, spondyloarthritis, ankylosing spondylitis, biologics, and epidemiology were the five most commonly used author keywords in the last decade.</p><p><strong>Discussion: </strong>Research on PSA has shown steady development from 2013 to 2023. High-income countries continue to dominate the field, which may be related to the level of economic development, medical resources, and health budgets. Articles published in the Annals of the Rheumatic Diseases have garnered more attention from individual internet users. The research focus has centered on the differential diagnosis, pathogenesis, treatment, and prevalence of the disease during this period, while biologic therapy, complications, and quality-of-life management are emerging as key trends.</p><p><strong>Conclusion: </strong>The research for PSA has been rapidly developing. The study analyzes the global status of PSA, identifies research hotspots in this field, and provides guidance for future research.</p>","PeriodicalId":11188,"journal":{"name":"Current rheumatology reviews","volume":" ","pages":"e15733971370078"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}